Suven Life Sciences receives product patents in New Zealand and Norway

Suven Life Sciences Ltd (Suven) informed the bourses on Tuesday that it has secures two product patents in New Zealand and Norway.

These patents are corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases. These patents are valid through 2034 (New Zealand) and 2027 (Norway).

Earlier in this month, the company has received the grant of the product patents from Australia, Eurasia and Europe.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products.

On Tuesday, the stock opened at Rs. 180.75 per share and touched an intraday high and low of Rs. 184.80 and Rs. 180.10, respectively, on the BSE.